留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

抑郁症的药物治疗进展

范志雄,  谢和辉

downloadPDF
文章导航 > 药学实践与服务  > 2012 >  30(3): 178-181
范志雄, 谢和辉. 抑郁症的药物治疗进展[J]. 药学实践与服务, 2012, 30(3): 178-181. doi: 10.3969/j.issn.1006-0111.2012.03.002
引用本文: 范志雄, 谢和辉. 抑郁症的药物治疗进展[J]. 药学实践与服务, 2012, 30(3): 178-181. doi: 10.3969/j.issn.1006-0111.2012.03.002
shu
FAN Zhi-xiong, XIE He-hui. Progress on drug treatment of depression[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 178-181. doi: 10.3969/j.issn.1006-0111.2012.03.002
Citation: FAN Zhi-xiong, XIE He-hui. Progress on drug treatment of depression[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 178-181. doi: 10.3969/j.issn.1006-0111.2012.03.002
shu

抑郁症的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2012.03.002
  • 1.

    第二军医大学研究生管理大队临床十队,上海 200433

  • 2.

    第二军医大学药学院药理学教研室,上海 200433

Progress on drug treatment of depression

  • 1.

    No.10 team of Clinical , Graduate Administration Division, Second Military Medical University, Shanghai 200433,China

  • 2.

    Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433,China

  • 摘要: 抑郁症是一种常见的精神疾病,其发病率在不断上升,而且难以治愈。目前抑郁症的治疗药物主要包括:三环类抗抑郁药、单胺氧化酶抑制剂和可逆性选择性单胺氧化酶抑制药、选择性5-HT再摄取抑制剂、选择性NE再摄取抑制剂、5-HT及NA再摄取抑制药、NA及DA再摄取抑制药等。本文就抗抑郁药及特殊情况下抑郁症的药物治疗进展作一综述。
    Abstract: Depression was a common mental disorder. Nowdays, anti-depressants included tricyclic antidepressants, monoamine oxidase inhibitors and reversible selective monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, selective noradrenergic reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, norepinephrine and dopamine reuptake inhibitors. The progress on drug treatment of depression were reviewed in this paper.
  • [1] Kessler RC,Berglund P,Demler O.The epidemiology of major depressive disorder:results from the national comorbidity survey replication(NCS-R)[J].JAMA, 2003, 89(2): 3095.
    [2] Kriston L, von Wolff A, Hlzel L. Effectiveness of psychotherapeutic, pharmacological,and combined treatments for chronic depression: a systematic review[J]. BMC Psychiatry, 2010, 10: 95.
    [3] Youdim MB, Weinstock M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation[J]. Neurotoxicology, 2004, 25(1-2): 243.
    [4] 郭 鹏, 丁素菊. 抗抑郁药物临床应用进展[J]. 药学服务与研究, 2009, 9(6): 405.
    [5] Tandt H, Audenaert K. SSRIs(selective serotonin reuptake inhibitors) and suicidality in adults, adolescents and children[J]. Tijdschr Psychiatr, 2009, 51(6): 387.
    [6] Baldwin D, Woods R. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis[J]. BMJ, 2011, 11: 342.
    [7] Mullins CD,Shaya FT.Comparison of first refill rates among users of sertrallne paroxetine, and citalopram[J]. Clin Ther, 2006, 28(2): 297.
    [8] Pogosova GV,Zhidko NI.Clinical effectiveness and safety of citalopram in patients with depression after myocardial infarction[J]. Kardiologiia, 2003, 43(1): 24.
    [9] Westenberq HG,Sandner C. Tolerability and safety of fluvoxamine and other antidepressants[J]. Int J Clin Pract, 2006, 60(4): 482.
    [10] Lundbeck H, Takeda P. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety[J]. Drugs, 2010, 13(12): 900.
    [11] Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials[J]. BMJ, 2010, 341: C4737.
    [12] Haine SE,Miljoen HP. Mianserin and ventricular tachycardia: case report and review of the literature[J]. Cardiology, 2006, 106(4): 195.
    [13] 朱宇欢.新型抗抑郁药的临床应用[J].中国医院用药评价与分析, 2010, 10(7): 669.
    [14] Aurora RN,Zak RS. Best practice guide for the treatment of nightmare disorder in adults[J]. J Clin Sleep Med, 2010, 6(4): 389.
    [15] Racagni G, Popoli M. The pharmacological properties of antidepressants[J]. Int Clin Psychopharmacol, 2010, 25(3):117.
    [16] Nakayama K. Mechanism of action of new generation antidepressants under development in Japan: focusing on dopamine neurotransmission[J]. Nihon Shinkei Seishin Yakurigaku Zasshi, 2009, 29(3): 99.
    [17] 陈瑞玲,赵志刚.抗抑郁症类药物的临床应用研究进展[J].中国临床药理学杂志,2007, 23(1): 54.
    [18] Girdler SS, Klatzkin R. Neurosteroids in the context of stress: Implications for depressive disorders[J]. Pharmacol Ther, 2007, 116: 125.
    [19] Gavioli EC, Calo'G. Antidepressant-and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands[J]. Naunyn Schmiedebergs Arch Pharmacol, 2006, 372: 319.
    [20] Catena-Dell'Osso M, Bellantuono C. Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development[J]. Curr Med Chem, 2011, 18(2): 245.
    [21] Joffe RT. Hormone treatment of depression[J]. Dialogues Clin Neurosci, 2011, 13(1): 127.
    [22] Freeman MP,Rapaport MH. Omega-3 fatty acids and depression: from cellular mechanisms to clinical care[J]. J Clin Psychiatry.2011,72(2):258.
    [23] Zavoreo I, Basic-Kes V. Post-stroke depression[J]. Acta Clin Croat, 2009, 48(3): 329.
    [24] 中国脑血管病防治指南编写委员会.中国脑血管病防治指南[M].北京:人民卫生出版社,2007,102.
    [25] Sondor H,Zsolt K.Clinical effectiveness and saftry of paroxetine in post-stroke depression[J]. Orv Hetil, 2006, 147(50): 2397.
    [26] Jassrsma T,Johansson P. Quality of life and symptoms of depression in advanced heart failure patients and their partners[J]. Curr Opin Support Palliat Care, 2010, 4(4): 233.
    [27] Marc L,Toureche N. Mind-body interventions during pregnancy for preventing or treating women's anxiety[J]. Cochrane Database Syst Rev, 2011, 7: CD007559.
    [28] Estrada-Camarena E,Lopez-Rubalcava C. Antidepressant effects of estrogens: a basic approximation[J]. Behav Pharmacol, 2010, 21(5-6): 451.
  • [1] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [2] 崔亚玲, 吴琼, 马良煜, 胡北, 姚东, 许子华.  肝素钠肌醇烟酸酯乳膏中肌醇烟酸酯皮肤药动学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404006
    [3] 陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠.  UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(8): 341-345. doi: 10.12206/j.issn.2097-2024.202404082
    [4] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [5] 岳春华, 贲永光, 王海桥.  基于NLRP1炎症小体探讨百合知母汤抗抑郁的作用机制 . 药学实践与服务, 2024, 42(8): 325-333. doi: 10.12206/j.issn.2097-2024.202401033
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  5416
  • HTML全文浏览量:  311
  • PDF下载量:  977
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-10-08
  • 修回日期:  2011-12-02

抑郁症的药物治疗进展

doi: 10.3969/j.issn.1006-0111.2012.03.002
  • 1. 第二军医大学研究生管理大队临床十队,上海 200433
  • 2. 第二军医大学药学院药理学教研室,上海 200433
  • 收稿日期: 2011-10-08
  • 修回日期: 2011-12-02

摘要: 抑郁症是一种常见的精神疾病,其发病率在不断上升,而且难以治愈。目前抑郁症的治疗药物主要包括:三环类抗抑郁药、单胺氧化酶抑制剂和可逆性选择性单胺氧化酶抑制药、选择性5-HT再摄取抑制剂、选择性NE再摄取抑制剂、5-HT及NA再摄取抑制药、NA及DA再摄取抑制药等。本文就抗抑郁药及特殊情况下抑郁症的药物治疗进展作一综述。

English Abstract

范志雄, 谢和辉. 抑郁症的药物治疗进展[J]. 药学实践与服务, 2012, 30(3): 178-181. doi: 10.3969/j.issn.1006-0111.2012.03.002
引用本文: 范志雄, 谢和辉. 抑郁症的药物治疗进展[J]. 药学实践与服务, 2012, 30(3): 178-181. doi: 10.3969/j.issn.1006-0111.2012.03.002
shu
FAN Zhi-xiong, XIE He-hui. Progress on drug treatment of depression[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 178-181. doi: 10.3969/j.issn.1006-0111.2012.03.002
Citation: FAN Zhi-xiong, XIE He-hui. Progress on drug treatment of depression[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 178-181. doi: 10.3969/j.issn.1006-0111.2012.03.002
shu

    全文HTML

参考文献 (28)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计